Phase 2 Autism Spectrum Disorder Trial, Recruiting NCT05664841 Sponsor: University of Alabama at Birmingham Condition: Autism Spectrum Disorder
Back to Autism Spectrum Disorder

Phase 2 Autism Spectrum Disorder Trial, Recruiting

NCT05664841
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have a confirmed autism diagnosis, with supporting evidence
  • Young people aged between 11 and 18 years old
  • People who have enough hand coordination and movement to perform magic tricks
  • People whose thinking and memory skills score above the expected level for their age on a standard children's cognitive assessment
  • People who have access to the internet and a computer or smartphone that can be used for video calls

Who may not be able to join:

  • People with serious hearing or vision difficulties that would prevent them from learning online
  • People who have previously taken part in an organised magic learning program or camp
  • People who are currently involved in, or planning to join, a psychological therapy program or another clinical trial during the study period that could influence the study results

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Hon Yuen, PhD, University of Alabama at Birmingham

Phone: 205-934-6301

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
27 March 2023
Est. completion
1 February 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Test of Adolescents Social Skills Knowledge (TASSK); Test of Adolescents Social Skills Knowledge (TASSK); Test of Adolescents Social Skills Knowledge (TASSK); Strengths and Difficulties Questionnaire (SDQ); Strengths and Difficulties Questionnaire (SDQ); Strengths and Difficulties Questionnaire (SDQ); Rosenberg Self Esteem Scale (RSES); Rosenberg Self Esteem Scale (RSES); Rosenberg Self Esteem Scale (RSES); UCLA Loneliness Scale Version 3; UCLA Loneliness Scale Version 3; UCLA Loneliness Scale Version 3; Self-efficacy Questionnaire for Children; Self-efficacy Questionnaire for Children; Self-e...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov